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Summary
 
We have previously shown that uncharacterized glycoprotein VI (GPVI), which is constitu-
tively associated and coexpressed with Fc receptor 
 
g
 
 chain (FcR
 
g
 
) in human platelets, is essen-
tial for collagen-stimulated tyrosine phosphorylation of FcR
 
g
 
, Syk, and phospholipase C
 
g
 
2
(PLC
 
g
 
2), leading to platelet activation. Here we investigated involvement of the Src family in
the proximal signals through the GPVI–FcR
 
g
 
 complex, using the snake venom convulxin
from 
 
Crotalus durissus terrificus
 
, which specifically recognizes GPVI and activates platelets
through cross-linking GPVI. Convulxin-coupled beads precipitated the GPVI–FcR
 
g
 
 complex
from platelet lysates. Collagen and convulxin induced tyrosine phosphorylation of FcR
 
g
 
, Syk,
and PLC
 
g
 
2 and recruited tyrosine-phosphorylated Syk to the GPVI–FcR
 
g
 
 complex. Using
coprecipitation methods with convulxin-coupled beads and antibodies against FcR
 
g
 
 and the
Src family, we showed that Fyn and Lyn, but not Yes, Src, Fgr, Hck, and Lck, were physically
associated with the GPVI–FcR
 
g
 
 complex irrespective of stimulation. Furthermore, Fyn was
rapidly activated by collagen or cross-linking GPVI. The Src family–specific inhibitor PP1
dose-dependently inhibited collagen- or convulxin-induced tyrosine phosphorylation of pro-
teins including FcR
 
g
 
, Syk, and PLC
 
g
 
2, accompanied by a loss of aggregation and ATP release
reaction. These results indicate that the Src family plays a critical role in platelet activation via
the collagen receptor GPVI–FcR
 
g
 
 complex.
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P
 
latelets adhere to collagen fibers of extracellular matrix
and become activated through specific membrane re-
ceptors, resulting in shape change, granule release, and ag-
gregation. These processes are vital for the formation of a
hemostatic plug under a physiologic or pathologic condi-
tion. Many platelet surface glycoproteins (GPs)
 
1
 
 have been
proposed as receptors for collagen, including the integrin
 
a
 
2
 
b
 
1
 
 (GPIaIIa; reference 1), GPIV (GPIIIb, CD36; refer-
ence 2), an uncharacterized protein GPVI (p62; references
3, 4), the type I collagen receptor (p65; reference 5), and
85–90-kD GPs (6). It has been well established that 
 
a
 
2
 
b
 
1
 
plays a major role in platelet adhesion to collagen (1), al-
though it remains unclear whether 
 
a
 
2
 
b
 
1
 
 directly transduces
signals leading to platelet activation. Our laboratory and
others have reported patients with mild bleeding disorders
whose platelets lack GPVI but not 
 
a
 
2
 
b
 
1
 
 and show selective
deficiency in collagen-induced platelet aggregation and re-
lease reaction (3, 4, 7). Several lines of evidence have dem-
onstrated that GPVI is implicated in collagen-induced
tyrosine phosphorylation of proteins (8–11), including Fc
receptor 
 
g
 
 chain (FcR
 
g
 
), Syk tyrosine kinase, and phos-
pholipase C
 
g
 
2 (PLC
 
g
 
2), which are essential for platelet ac-
tivation upon collagen stimulation (12–14). GPVI is consti-
tutively associated with FcR
 
g
 
 (10, 11), while both of them
are proportionally absent in GPVI-deficient platelets (10),
suggesting their coexpression. Cross-linking GPVI by the
F(ab
 
9
 
)
 
2
 
 of anti-GPVI IgG (anti-GPVI F(ab
 
9
 
)
 
2
 
) stimulates ty-
rosine phosphorylation of FcR
 
g
 
, Syk, and PLC
 
g
 
2, and re-
 
1
 
Abbreviations used in this paper:
 
 anti-GPVI F(ab
 
9
 
)
 
2
 
, the F(ab
 
9
 
)
 
2
 
 of anti-
GPVI IgG; FcR
 
g
 
, Fc receptor 
 
g
 
 chain; Fc
 
g
 
RII, low affinity Fc receptor
for IgG; Fc
 
e
 
RI, high affinity Fc receptor for IgE; GP, glycoprotein;
GPVI, glycoprotein VI; ITAM, immunoreceptor tyrosine-based activa-
tion motif; PLC
 
g
 
2, phospholipase C
 
g
 
2; PP1, 4-amino-5-(4-methylphe-
nyl)-7-(
 
t
 
-butyl)pyrazolo[3,4-
 
d
 
]pyrimidine; RGDS, Arg-Gly-Asp-Ser; RIPA,
radioimmunoprecipitation assay.
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cruits Syk to FcR
 
g
 
, leading to Syk activation (8, 10, 11),
whereas GPVI-deficient platelets specifically lack activation
of Syk in response to collagen (9). These findings have re-
vealed the GPVI–FcR
 
g
 
 complex as a collagen receptor re-
sponsible for platelet activation.
To further investigate the mechanisms involved in the
proximal signals through the GPVI–FcR
 
g
 
 complex, we used
the snake venom convulxin from 
 
Crotalus durissus terrificus
 
,
which has been known to be a powerful platelet activator
(15, 16), and the Src family-specific inhibitor PP1 (4-amino-
5-(4-methylphenyl)-7-(
 
t
 
-butyl)pyrazolo[3,4-
 
d
 
]pyrimidine; ref-
erence 17). Recent reports have shown that convulxin is a
heterodimeric C-type lectin and binds to platelet surface
with a high affinity on a small number of binding sites (18,
19), that 
 
125
 
I-convulxin specifically recognizes a glycosyl-
ated 62-kD membrane protein immunoprecipitated by the
anti-GPVI IgG (18, 20), and that cross-linking GPVI with
convulxin induces tyrosine phosphorylation of proteins in-
cluding FcR
 
g
 
, Syk, and PLC
 
g
 
2 (18). In this report, we
demonstrated that the Src family tyrosine kinases Fyn and
Lyn were physically associated with the GPVI–FcR
 
g
 
 com-
plex and that Fyn was activated by collagen stimulation or
cross-linking GPVI. PP1 dose-dependently inhibited col-
lagen- or convulxin-induced tyrosine phosphorylation of
proteins including FcR
 
g
 
, Syk, and PLC
 
g
 
2, accompanied
by a loss of aggregation and ATP release reaction. Analogy
to the antigen and Fc receptor signals, the Src family kinases
were involved in platelet activation through the collagen
receptor GPVI coupled with FcR
 
g
 
 as a signal transducing
subunit containing an immunoreceptor tyrosine-based acti-
vation motif (ITAM; references 21, 22).
 
Materials and Methods
 
Reagents.
 
Convulxin was purified with gel filtration chroma-
tography as described by Polgár et al. (18) from lyophilized 
 
Crota-
lus durissus terrificus
 
 venom obtained from Sigma Chemical Co.
(St. Louis, MO). CNBr-activated Sepharose 4B beads, Sepharose
4B beads, and protein A–Sepharose beads were purchased from
Pharmacia Biotechnology Inc. (Uppsala, Sweden). As previously
described, human anti-GPVI IgG and its F(ab
 
9
 
)
 
2
 
 fragments were
prepared from serum of a patient with GPVI deficiency (3, 8),
who has been followed up as an outpatient in our department.
Anti-FcR
 
g
 
 IgG was produced by immunizing rabbits with a syn-
thetic peptide (residues 80–86) from FcR
 
g
 
 as described previ-
ously (23). mAbs against Syk (clone Syk101), Lyn (clone Lyn9),
and Yes (clone 3H9) were purchased from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan). Anti-phosphotyrosine (clone 4G10)
and anti-Src (clone 327) mAbs were obtained from Upstate Bio-
technology, Inc. (Lake Placid, NY) and Oncogene Science, Inc.
(Uniondale, NY), respectively. Anti–low affinity Fc receptor for
IgG (Fc
 
g
 
RII) mAb (clone IV.3) was from Medarex Inc. (Annan-
dale, NJ). Affinity-purified rabbit IgG specific to Fyn (FYN3),
Hck (N-30), and PLC
 
g
 
2 (C19) and affinity-purified goat IgG to
Lck (2102) were purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). Affinity-purified rabbit anti-Fgr Ab was ob-
tained from Transduction Laboratories (Lexington, KY). Mouse
mAb (clone 19-1; reference 24) against the 
 
a
 
 chain of human
high affinity Fc receptor for IgE (Fc
 
e
 
RI) was a kind gift from Dr.
M.-H. Jouvin and Dr. J.-P. Kinet (Beth Israel Hospital, Boston,
MA). Acid soluble fibrillar collagen prepared from equine tendon
was purchased from Horm-Chemie (Munich, Germany). PP1
(17) and PGE
 
1
 
 were kindly provided by Pfizer Central Research
(Groton, CT) and Ono Pharmaceutical Co. (Osaka, Japan), re-
spectively. Arg-Gly-Asp-Ser (RGDS) and enolase were obtained
from Sigma Chemical Co. 
 
g
 
-[
 
32
 
P]ATP (3,000 Ci/mmol, 10
mCi/ml) was supplied by DuPont NEN (Boston, MA). All other
reagents were obtained as previously reported (25).
 
Preparation and Stimulation of Platelets.
 
After informed con-
sent was obtained, venous blood was collected from healthy adult
donors. All experiments involving human subjects were conducted
according to the principles expressed in the Declaration of Hels-
inki. Anticoagulation of blood and preparation of platelet-rich
plasma were performed as described previously (26). Platelet-rich
plasma was incubated with 1 mM aspirin for 30 min at 37
 
8
 
C.
Gel-filtered platelets were then prepared as described previously
(27) at a final concentration of 1 
 
3 
 
10
 
9
 
 cells/ml in Hepes buffer
(137 mM NaCl, 2.7 mM KCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 5.6 mM
glucose, 1 mg/ml BSA, 3.3 mM NaH
 
2
 
PO
 
4
 
, and 20 mM Hepes,
pH 7.4), containing 1 U/ml apyrase and 500 
 
m
 
M RGDS to avoid
secondary effects via released ADP and aggregation. Platelets
were stimulated by 50 
 
m
 
g/ml of collagen, 50 ng/ml of convulxin,
or 150 
 
m
 
g/ml of anti-GPVI F(ab
 
9
 
)
 
2
 
 with gentle agitation for ap-
propriate periods at 37
 
8
 
C. In some experiments, gel-filtered
platelets were incubated for 3 min at 37
 
8
 
C with indicated con-
centrations of PP1 or DMSO (0.25%) as a control before stimu-
lation. Resting or stimulated platelets were lysed with an equal
volume of ice-cold 2
 
3
 
 Triton X-100 lysis buffer (150 mM NaCl,
10 mM EGTA, 2% Triton X-100, 2 mM PMSF, 2 mM Na
 
3
 
VO
 
4
 
,
40 
 
m
 
g/ml leupeptin, 40 
 
m
 
g/ml aprotinin, and 20 mM Hepes, pH
7.4) or 2
 
3
 
 radioimmunoprecipitation assay (RIPA) buffer (150
mM NaCl, 10 mM EGTA, 2% Triton X-100, 2% sodium deoxy-
cholate, 0.2% SDS, 2 mM PMSF, 2 mM Na
 
3
 
VO
 
4
 
, 40 
 
m
 
g/ml leu-
peptin, 40 
 
m
 
g/ml aprotinin, and 20 mM Hepes, pH 7.4). For
preparation of whole platelet lysates, gel-filtered platelets were
suspended in Hepes buffer without BSA and directly lysed in an
equal volume of 2
 
3
 
 SDS sample buffer (
 
3
 
1; 2% SDS, 5% glyc-
erol, 5% 
 
b
 
-ME, and 62.5 mM Tris-HCl, pH 6.8), and boiled for
5 min.
 
Affinity Precipitation of Convulxin-binding Proteins.
 
100 
 
m
 
g of
purified convulxin was covalently coupled to 1 ml of CNBr-acti-
vated Sepharose 4B beads according to the manufacturer’s in-
structions. 1.2 ml of platelet lysates (from 6 
 
3 
 
108 cells/sample)
was clarified by centrifugation at 16,000 g for 30 min, incubated
for 1 h with 40 ml of Sepharose 4B (50% slurry), and then pre-
cleared by sedimentation at 16,000 g for 30 min. These steps and
all subsequent steps were carried out at 48C. The supernatants
were incubated for 1 h with 40 ml of convulxin-coupled
Sepharose 4B (50% slurry) or Sepharose 4B as a control. The
beads were sedimented by brief centrifugation and washed four
times in lysis buffer containing 0.5 M NaCl. Proteins were eluted
from the beads in 90 ml of SDS sample buffer and boiled for 5 min.
Immunoprecipitation. Immunoprecipitation of each protein
and its associated proteins was performed as described previously
(25), followed by two-step elution with different buffers. 1.2 ml
of lysates prepared from 6 3 108 platelets in Triton X-100 lysis
buffer was clarified by centrifugation at 16,000 g for 30 min, pre-
cleared with protein A–Sepharose beads, and incubated for 2 h
with 5 mg of anti-FcRg IgG, preimmune rabbit IgG, anti-FcgRII
mAb, anti-Fyn Ab, anti-Lyn mAb, anti-Yes mAb, anti-Src mAb,
and anti-PLCg2 Ab. This step and all subsequent steps were per-
formed at 48C. For immunoprecipitation of Yes and Src, lysates
were further incubated for 1 h with 25 mg of rabbit anti–mouse269 Ezumi et al.
IgG. Immune complexes were then precipitated with protein
A–Sepharose beads for 1 h, sedimented by brief centrifugation,
and washed four times in Triton X-100 lysis buffer. Coprecipi-
tated proteins were first eluted in 60 ml of RIPA buffer. Eluates
were diluted with 30 ml of 33 SDS sample buffer and boiled for
5 min. The left beads were further washed four times in RIPA
buffer. Immunoprecipitates were then eluted in 60 ml of SDS
sample buffer and boiled for 5 min. These samples eluted by SDS
sample buffer were checked with immunoblotting whether each
Ab precipitated its recognizing protein.
Immunoblotting. Immunoblot analysis for each protein was
done as described previously (25). In brief, samples (the whole
platelet lysates from 5 3 106 cells/lane or affinity precipitates and
immunoprecipitates from 1 3 108 cells/lane) were subjected to
10% SDS-PAGE and transferred electrophoretically to nitrocellu-
lose membranes (Bio-Rad Laboratories, Hercules, CA) with a
semidry blotter. For detection of FcRg, samples were resolved
on 12.5% SDS-PAGE with Tris-Tricine buffer system. The
membranes were treated with Ab against phosphotyrosine (1 mg/
ml), GPVI (2.5 mg/ml), FcRg (1 mg/ml), a chain of FceRI (0.5 mg/
ml), Syk (2 mg/ml), Fyn (1 mg/ml), Lyn (5 mg/ml), Yes (1 mg/ml),
Src (0.2 mg/ml), Fgr (1 mg/ml), Hck (2 mg/ml), Lck (1 mg/ml), or
PLCg2 (1 mg/ml), followed by the ECL chemiluminescence re-
action (Amersham International plc., Little Chalfont, UK). For
detection of GPVI, anti-GPVI IgG was biotinylated to enhance
sensitivity (10). The densities of some protein bands on scanned
images were analyzed using the public domain NIH Image pro-
gram (written by Wayne Rasband at the National Institutes of
Health).
Immune Complex Kinase Assay. To examine in vitro kinase
activity of Fyn and Lyn, the kinases were isolated by immunopre-
cipitation with 1 mg of specific Abs as described above from
platelet lysates (from 3 3 108 cells/sample) prepared in RIPA
buffer. Immunoprecipitates were washed four times with RIPA
buffer and twice with kinase buffer (20 mM Hepes, pH 7.5, and
10 mM MnCl2), and then incubated for 5 min at room tempera-
ture with 10 mg of acid-treated enolase in 30 ml of kinase buffer
including 5 mCi of g-[32P]ATP and 1 mM of ATP. Reactions
were stopped by addition of 30 ml of 23 SDS sample buffer. The
samples were boiled for 3 min and subjected to 10% SDS-PAGE.
Radioactivity of each protein was visualized and quantified with
the Bio-Imaging Analyzer BAS-2000II (Fuji Photo Film Co.,
Tokyo, Japan).
Platelet Aggregation and ATP Release Reaction. Gel-filtered plate-
lets  were prepared from platelet-rich plasma as described above
but without aspirin pretreatment, suspended at a final concentra-
tion of 3 3 108 cells/ml in Hepes buffer without RGDS, and in-
cubated with PP1 or DMSO for 3 min at 378C before stimulation
by collagen, convulxin, or thrombin. Standard aggregometry of
platelets was performed according to the Born method (28) in an
aggregometer (HEMA TRACER 1; Nikko Bioscience, Tokyo,
Japan). Release reaction from dense granules of platelets was
monitored as ATP release using luciferin-luciferase reaction in a
lumi-aggregometer (Chrono-Log, Harverton, PA) as described
previously (8).
Results
Precipitation of the GPVI–FcRg Complex with Convulxin-
coupled Beads from Platelet Lysates. Convulxin specifically
and strongly binds GPVI expressed on the platelet surface
(19). 125I-convulxin also specifically recognizes GPVI blot-
ted on polyvinylidene difluoride or nitrocellulose mem-
branes (18, 20). Here we used Sepharose 4B beads that
were covalently coupled with convulxin to isolate GPVI
and associated proteins from platelet lysates. Immunoblot
analysis showed that convulxin-coupled Sepharose 4B but
not Sepharose 4B alone effectively precipitated both GPVI
and FcRg, which are constitutively associated with each
other (10, 11), when we used Triton X-100 lysis buffer
(Fig. 1, A and B). If we used more stringent RIPA buffer to
solubilize platelets, only GPVI but not FcRg was precipi-
tated with convulxin-coupled Sepharose 4B from platelet
lysates (data not shown). These findings indicate that GPVI
and FcRg were dissociated in RIPA buffer and that con-
vulxin directly and strongly binds to GPVI. Thus, we used
Triton X-100 lysis buffer to analyze molecules associated
with the GPVI–FcRg complex in the rest of studies.
Collagen- or Convulxin-induced Tyrosine Phosphorylation of Pro-
teins Associated with the GPVI–FcRg Complex. Collagen, con-
vulxin, and anti-GPVI F(ab9)2 stimulate tyrosine phosphor-
ylation of signaling molecules including FcRg, Syk, and
PLCg2, which are essential for platelet activation by these
agonists (8–14, 18). Recent studies have shown that
convulxin activates platelets via cross-linking GPVI (18,
20). We examined tyrosine phosphorylation of proteins co-
precipitated with the GPVI–FcRg complex purified by
convulxin-coupled Sepharose 4B from intact platelets and
platelets stimulated by collagen or convulxin. Upon col-
lagen and convulxin stimulation, we observed an increase
in tyrosine phosphorylation of proteins with molecular
masses of 140, 95, 85, 72, 53/60, and 10/12 kD (Fig. 2 A).
We confirmed that the 72-kD band corresponded to accu-
Figure 1. Affinity precipitation of the GPVI–FcRg complex with con-
vulxin-coupled Sepharose 4B from platelet lysates. Unstimulated gel-filtered
platelets were lysed directly in SDS sample buffer or in Triton X-100 lysis
buffer. Whole lysates (lane 1) and proteins precipitated by affinity with
convulxin-coupled Sepharose 4B (lane 2) or Sepharose 4B alone (lane 3)
were resolved by 10% (A) or 12.5% SDS-PAGE (B), transferred to nitro-
cellulose membranes, and immunoblotted with anti-GPVI IgG (A) or
anti-FcRg IgG (B). Molecular mass markers are indicated in kD on the
right of panels.270 Involvement of the Src Family in Platelet Activation by Collagen
mulation of tyrosine-phosphorylated Syk (Fig. 2 B) and
that the 10/12-kD doublets were FcRg, which showed
mobility retardation on SDS-PAGE due to phosphoryla-
tion (Fig. 2 D). GPVI, whose molecular mass is 62 kD
under the reduced condition (3, 4, 8), was equally precipi-
tated (Fig. 2 C) but not tyrosine phosphorylated irrespective
of stimulation as previously reported (8, 10). Whereas col-
lagen and convulxin stimulated tyrosine phosphorylation of
PLCg2 as previously reported (8, 14, 18, 29, 30), we could
not detect PLCg2 in the precipitated proteins with con-
vulxin-coupled Sepharose 4B regardless of stimulation (data
not shown).
Physical Association of Fyn and Lyn with the GPVI–FcRg
Complex. We next focused on the heavily tyrosine-phos-
phorylated proteins with molecular masses of 53–60 kD.
The Src family kinases are cytosolic protein tyrosine kinases
with molecular masses z60 kD and usually tyrosine phos-
phorylated themselves. Previous reports have shown that
platelets abundantly express the Src family kinases including
Src, Fyn, Yes, Lyn, Hck, Fgr, and Lck (31–36). We then
examined whether the Src family kinases existed in the pre-
cipitated proteins with convulxin-coupled Sepharose 4B by
immunoblotting with Ab specific to each kinase. Fig. 3
shows that convulxin-coupled Sepharose 4B precipitated
Fyn (59 kD) and Lyn (53–56 kD), but not Yes (62 kD), Src
(60 kD), Fgr (59 kD), and Lck (56 kD, data not shown),
from lysates of resting platelets and collagen- or convulxin-
stimulated platelets. Upon stimulation, protein levels of
precipitated Fyn and Lyn did not change (Fig. 3, A and B).
Sepharose 4B alone as a control precipitated none of these
kinases (Fig. 3). We could not detect Hck with immuno-
blotting in whole platelet lysates or in the precipitated pro-
teins with convulxin-coupled Sepharose 4B (data not
shown). To confirm whether Fyn and Lyn precipitated
with convulxin-coupled Sepharose 4B were associated
with the GPVI–FcRg complex, we next analyzed proteins
coimmunoprecipitated with anti-FcRg IgG and Abs
against the Src family kinases. There was a problem that H
chain of IgG used for immunoprecipitation overlapped the
Src family kinases or GPVI on immunoblots due to their
similar molecular masses. Hence, RIPA buffer was used to
elute only coprecipitated proteins from immunoprecipitates
as described in Materials and Methods, since RIPA buffer
could not elute IgG and its recognizing proteins from im-
mune complexes bound to protein A–Sepharose beads
(data not shown). Fyn and Lyn but not Src were coimmu-
noprecipitated with anti-FcRg IgG from platelet lysates
(Fig. 4, A–C). Yes, Fgr, Hck, and Lck were not detected in
coimmunoprecipitates with anti-FcRg IgG (data not
shown). Conversely, anti-Fyn or anti-Lyn Ab, but not
anti-Yes or anti-Src mAb coimmunoprecipitated both
GPVI and FcRg (Fig. 4, D and E). These data clearly dem-
onstrate that Fyn and Lyn were constitutively and specifi-
cally associated with the GPVI–FcRg complex. Because
very recent studies indicated that platelets heterogeneously
express FceRI (37, 38), which is associated with FcRg and
Lyn in other cells (39, 40), we examined whether FceRI
existed in the precipitated proteins with convulxin-coupled
Sepharose 4B. We did not detect the a chain of FceRI
among them with immunoblotting (data not shown). Al-
though collagen stimulates tyrosine phosphorylation of
FcgRIIA in platelets (14), convulxin did not induce it (data
Figure 2. Tyrosine phosphorylation of proteins coprecipitated with the
GPVI–FcRg complex in collagen- and convulxin-stimulated platelets.
Gel-filtered platelets were unstimulated (lane 1) or stimulated for 1 min at
378C with 50 mg/ml of collagen (lane 2) or 50 ng/ml of convulxin (lanes
3 and 4) and lysed in Triton X-100 lysis buffer. Precipitated proteins with
convulxin-coupled Sepharose 4B (lane 1–3) or Sepharose 4B (lane 4)
were resolved by 10% (A, top, B, and C) or 12.5% SDS-PAGE (A, bottom
and  D), transferred to nitrocellulose membranes, and immunoblotted
with Abs against phosphotyrosine (A), Syk (B), GPVI (C), and FcRg (D).
Molecular mass markers are indicated in kD on the right of panels. In A
(bottom) and D open and closed arrows mark unphosphorylated and phos-
phorylated FcRg, respectively.
Figure 3. Coprecipitation of Fyn and Lyn, but not Yes, Src, and Fgr,
with the GPVI–FcRg complex from platelet lysates. Gel-filtered platelets
were unstimulated (lanes 1 and 2) or stimulated for 1 min at 378C with 50
mg/ml of collagen (lane 3) or 50 ng/ml of convulxin (lanes 4 and 5) and
lysed in Triton X-100 lysis buffer (lanes 2–5) or directly in SDS sample
buffer (lane 1). Whole lysates (lane 1) and precipitated proteins with con-
vulxin-coupled Sepharose 4B (lanes 2–4) or Sepharose 4B (lane 5) were
resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes,
and immunoblotted with Abs against Fyn (A), Lyn (B), Yes (C), Src (D),
and Fgr (E).271 Ezumi et al.
not shown). Convulxin-coupled Sepharose 4B did not co-
precipitate FcgRIIA (data not shown), confirming our pre-
vious findings that it is not associated with the GPVI–FcRg
complex (10).
Rapid Activation of Fyn upon Collagen Stimulation or GPVI
Cross-linking. Next we examined whether collagen stim-
ulation or cross-linking GPVI activated Fyn and Lyn. Fyn
and Lyn were immunoprecipitated and subjected to an in
vitro kinase assay with enolase as an exogenous substrate.
We confirmed with immunoblotting that an equal amount
of each kinase was immunoprecipitated (data not shown).
Judging from both autophosphorylating activity and kinase
activity toward enolase, Fyn was very rapidly activated by
collagen stimulation or by cross-linking GPVI with con-
vulxin or anti-GPVI F(ab9)2 (Fig. 5, A–C). Activation of
Fyn reached the maximum level at 10 s and returned to the
basal level within 60 s upon stimulation of convulxin or
anti-GPVI F(ab9)2, whereas collagen-stimulated activation
of Fyn was observed through 2 min of stimulation. We did
not detect an increase in kinase activity of Lyn by collagen
or cross-linking GPVI (data not shown). In some but not
all experiments, we observed a slight decrease in kinase ac-
tivity of Lyn upon convulxin (Fig. 5 D) or collagen stimu-
lation (data not shown).
Inhibition of the Collagen- or Convulxin-induced Protein Tyro-
sine Phosphorylation by the Src Family-specific Inhibitor PP1.
We used the Src family-specific inhibitor PP1 (17) to ex-
amine whether activation of Src family kinases was in-
volved in the collagen- or convulxin-induced tyrosine
phosphorylation of molecules including FcRg, Syk, and
PLCg2. Gel-filtered platelets were preincubated with or
without various concentrations of PP1 for 3 min and then
stimulated with 50 mg/ml of collagen or 50 ng/ml of con-
vulxin for appropriate times. Whole lysates were prepared
from those platelets and subjected to the analysis of immu-
noblotting with anti-phosphotyrosine mAb (Fig. 6). Col-
lagen stimulation induced tyrosine phosphorylation of pro-
teins with molecular masses of 140, 120, 100, 85, 72/75,
65, 38/40, and 28/30 kD. Preincubation of platelets with
PP1 inhibited the collagen-induced tyrosine phosphoryla-
tion of these proteins in a dose-dependent manner (Fig. 6
A). Convulxin stimulation induced tyrosine phosphoryla-
tion of proteins with the same molecular masses as de-
scribed above, but the intensity of those protein bands was
much stronger than upon collagen stimulation (Fig. 6 B).
Preincubation of platelets with PP1 also inhibited the con-
vulxin-induced tyrosine phosphorylation in a dose-depen-
dent manner as was observed with collagen stimulation
(Fig. 6 B). The heavily tyrosine-phosphorylated 60-kD
protein band in both resting and activated platelets corre-
sponded to Src with immunoblotting analysis (data not
shown). Next we examined the effects of PP1 on the col-
lagen- or convulxin-induced tyrosine phosphorylation of
FcRg, Syk, and PLCg2 in platelets. PP1 (1–20 mM) dose-
dependently inhibited the collagen-stimulated tyrosine phos-
Figure 4. Coimmunoprecipita-
tion of Fyn and Lyn with anti-
FcRg IgG and coimmunopre-
cipitation of GPVI and FcRg
with anti-Fyn and anti-Lyn Abs.
Unstimulated gel-filtered plate-
lets were lysed directly in SDS
sample buffer or in Triton X-100
lysis buffer. (A–C) Whole lysates
(lane 1) and immunoprecipitates
with preimmune rabbit IgG
(lane  2) and anti-FcRg IgG (lane
3) were resolved by 10% SDS-
PAGE, transferred to nitrocellu-
lose membranes, and immuno-
blotted with Abs against Fyn (A),
Lyn (B), and Src (C). (D and E)
Whole lysates (lane 1) and im-
muno-precipitates with Abs
against  Fyn (lane 2), Lyn (lane 3),
Yes (lane 4), and Src (lane 5)
were resolved by 10% (D) or
12.5% (E) SDS-PAGE, trans-
ferred to nitrocellulose mem-
branes, and immunoblotted with
anti-GPVI IgG (D) and anti-
FcRg IgG (E).
Figure 5. Kinase activity of Fyn and Lyn in platelets stimulated by col-
lagen, convulxin, or anti-GPVI F(ab9)2. Gel-filtered platelets were stimu-
lated for the indicated periods at 378C with collagen (A, 50 mg/ml), con-
vulxin (B and D, 50 ng/ml), or anti-GPVI F(ab9)2 (C, 150 mg/ml) and
lysed in RIPA buffer. Fyn (A–C) and Lyn (D) were immunoprecipitated
from lysates and subjected to in vitro kinase assay with enolase as an exog-
enous substrate, followed by 10% SDS-PAGE. Radioactivity of each pro-
tein was visualized (A–D) and quantified with the Bio-Imaging Analyzer
BAS-2000II. Kinase activity toward enolase was calculated (H). Positions
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phorylation of GPVI-associated FcRg (Fig. 7 C) as well as
the recruitment of tyrosine-phosphorylated Syk to the
GPVI–FcRg complex (Fig. 7, A and B). We confirmed
that convulxin-coupled Sepharose 4B equally precipitated
both GPVI and FcRg, irrespective of PP1 pretreatment
(Fig. 7, D and E). PP1 also reduced collagen-stimulated ty-
rosine phosphorylation of PLCg2 in a dose-dependent
fashion (Fig. 7 F). Essentially similar results on the PP1 ef-
fects were obtained with convulxin-stimulated platelets
(data not shown).
Inhibition of the Collagen- or Convulxin-induced Aggregation
and ATP Release Reaction by PP1. To investigate functional
involvement of the Src family kinases in platelet activation
through the GPVI–FcRg complex, we examined the ef-
fects of PP1 on aggregation and ATP release reaction upon
collagen or convulxin stimulation. PP1 alone did not cause
any shape change, aggregation, or ATP release up to 20 mM
of concentrations (data not shown). PP1 ranging in con-
centrations from 1 to 10 mM dose-dependently inhibited
aggregation and ATP release caused by 2 mg/ml of collagen
(Fig. 8, A and a), whereas PP1 little affected the extent of
shape change but markedly delayed it (Fig. 8 A). Similar
findings were also obtained when platelets were pretreated
with 1–10 mM of PP1 and stimulated with 10 ng/ml of
convulxin (Fig. 8, B and b). In contrast, 20 mM of PP1 did
not affect aggregation and ATP release induced by 0.1 U/ml
of thrombin (Fig. 8, C and c).
Discussion
Because the snake venom convulxin specifically binds to
GPVI (18, 20), we used convulxin-coupled Sepharose 4B
beads for affinity precipitation of the GPVI–FcRg complex
and associated proteins from platelet lysates. Convulxin-
coupled Sepharose 4B efficiently precipitated GPVI, FcRg,
and their associated proteins such as Syk. We also found
that collagen or convulxin stimulation induced tyrosine
phosphorylation of FcRg associated with GPVI and re-
cruitment of Syk to the GPVI–FcRg complex, confirming
the complex as a collagen receptor. These experiments
showed that convulxin-coupled Sepharose 4B was a pow-
erful tool to isolate and study the GPVI–FcRg complex.
We noticed that convulxin-coupled Sepharose 4B copre-
cipitated tyrosine-phosphorylated proteins with molecular
masses of 53–60 kD with the GPVI–FcRg complex. It has
been established that the Src family tyrosine kinases are essen-
tial for generating initial signals through the immune recep-
tors, which consist of ITAM-containing subunits, leading
to tyrosine phosphorylation of ITAMs and Syk activation
(22, 39, 40). Platelets abundantly express the Src family ki-
nases, whose molecular masses are 53–62 kD and usually
tyrosine phosphorylated (31–36). Using coprecipitation
methods with convulxin-coupled Sepharose 4B, anti-FcRg
IgG, and Abs to the Src family kinases, we clearly showed
that Fyn and Lyn, but not Yes, Src, Fgr, Hck, and Lck,
were constitutively associated with the GPVI–FcRg com-
plex, irrespective of stimulation. Although GPIV (CD36) is
also stably associated with Fyn, Lyn, and Yes in platelets
(36), GPIV is not associated with either GPVI or FcRg
(10). Recent reports showed that platelets heterogeneously
express FceRI (37, 38), which consists of the a, b, and g
chains, and is associated with Lyn in other cells such as mast
cells (39, 40). However, we denied association of the a
chain of FceRI with the GPVI–FcRg complex. FcgRIIA,
which is another ITAM-containing receptor in platelets, is
not associated with the GPVI–FcRg complex (10). These
data indicate that the GPVI–FcRg complex is a newly
identified receptor that is physically associated with the Src
family kinases in platelets.
Rapid activation of Src (41) and Lyn (42) but not of Fyn
has been previously reported in thrombin-stimulated plate-
lets under specific experimental conditions, such as weak
stimulation or specified lysis buffers. We have reported that
Src is activated upon collagen stimulation or cross-linking
GPVI (8, 9). In addition, here we showed for the first time
that Fyn became rapidly activated by collagen or cross-
linking GPVI. We could detect the Src activation only if
we used 1% Triton X-100 containing lysis buffer to lyse
platelets as previously reported (8, 9). In contrast to Src, we
could observe the Fyn activation only if we used RIPA
buffer as described in Materials and Methods. However, we
could not detect Lyn activation by collagen stimulation or
cross-linking GPVI with either RIPA buffer or Triton X-100
lysis buffer. It has been well documented that members
of the Src family kinases are differently distributed in rest-
ing platelets (35) and relocate to the membrane skeleton or
Figure 6. The Src family-specific inhibitor
PP1 dose-dependently inhibits collagen- or
convulxin-induced tyrosine phosphorylation of
whole lysates. Gel-filtered platelets were prein-
cubated for 3 min at 378C with 0.25% DMSO
(lanes 1 and 2) or the indicated concentrations
of PP1 (lanes 3–7). Platelets were unstimulated
(lane 1) or stimulated with 50 mg/ml of collagen
for 30 s (A, lanes 2–7) or 50 ng/ml of convulxin
for 15 s (B, lanes 2–7), directly lysed in SDS
sample buffer, resolved by 10% SDS-PAGE,
transferred to nitrocellulose membranes, and im-
munoblotted with anti-phosphotyrosine mAb.
Molecular mass markers are indicated in kD on
the right of panels. Arrows mark the position
of Src.273 Ezumi et al.
the cytoskeleton (41–44), which is insoluble in 1% Triton
X-100 containing lysis buffer, upon stimulation. These dif-
ferent natures of the kinases may cause the different re-
quirements for lysis buffers to detect their activation. We
observed a slight decrease in kinase activity of Lyn upon
convulxin or collagen stimulation in some but not all ex-
periments. Such a decrease in Lyn activity seems to be sim-
ilar to Src activity as reported previously (9, 41). Although
Src is activated by either collagen or cross-linking GPVI in
normal platelets, Src is still activated by collagen in GPVI-
deficient platelets lacking collagen-induced Syk activation
and PLCg2 phosphorylation (9). Taken together with our
new findings that Src was not physically associated with the
GPVI–FcRg complex, Src does not seem to be directly in-
volved at least in Syk activation and subsequent tyrosine
phosphorylation of PLCg2 upon collagen stimulation.
It has been demonstrated that PP1 selectively inhibits the
Src family kinases, including Lck, Fyn, Src, Hck, and Lyn,
but not the Syk family kinases, including ZAP-70 and Syk,
even at concentrations over 100 mM (17, 45). We observed
that PP1 (1–20 mM) dose-dependently inhibited collagen-
or convulxin-induced tyrosine phosphorylation of whole
lysates. PP1 also abolished tyrosine phosphorylation of
GPVI-associated FcRg, Syk, and PLCg2 as well as recruit-
ment of Syk to the GPVI–FcRg complex. The concentra-
tions of PP1 used here were similar ones that have been re-
ported to inhibit induction of tyrosine phosphorylation or
cell functions upon stimulation in T cells, RBL-2H3 cells,
fibroblasts, or Mo7e cells (17, 45–47). As for immune re-
ceptors, it has been reported that FcRg is phosphorylated
on tyrosine by the Src family kinases that are associated
with the receptors, such as Lyn for FceRI (22, 39, 40).
Therefore, Fyn and Lyn that were associated with the
GPVI–FcRg complex would be most probable candidate
kinases responsible for phosphorylating FcRg and subse-
quent signals in GPVI-mediated platelet activation by col-
lagen. Finally, we showed that PP1 inhibited collagen- or
convulxin-stimulated aggregation and ATP release reaction
Figure 7. PP1 dose-dependently inhibits collagen-induced Syk recruit-
ment and tyrosine phosphorylation of FcRg and PLCg2. Gel-filtered
platelets were preincubated for 3 min at 378C with 0.25% DMSO (lanes 1
and 2) or the indicated concentrations of PP1 (lanes 3–6). Platelets were
unstimulated (lane 1) or stimulated with 50 mg/ml of collagen for 30 s
(lanes 2–6) and lysed in Triton X-100 lysis buffer. Precipitated proteins
with convulxin-coupled Sepharose 4B (A–E) or immunoprecipitates with
anti-PLCg2 Ab (F and G) were resolved by 10% (A, B, and E–G) or
12.5% (C and D) SDS-PAGE, transferred to nitrocellulose membranes,
and immunoblotted with Abs against phosphotyrosine (A, C, and F), Syk
(B), FcRg (D), GPVI (E), and PLCg2 (G). In H the band densities from
tyrosine-phosphorylated Syk (A), FcRg (C), and PLCg2 (F) were quanti-
fied and graphed as a percentage of the band density in lane 2 of each
panel. The position of each protein is indicated on the right of panels.
Figure 8. PP1 dose-dependently inhibits collagen- or convulxin-
induced aggregation and ATP release reaction. Gel-filtered platelets were
preincubated for 3 min at 378C with 0.25% DMSO or various concentra-
tions of PP1 (mM) as indicated. Platelets were stimulated with 2 mg/ml of
collagen (A and a), 10 ng/ml of convulxin (B and b), or 0.1 U/ml of
thrombin (C and c) under constant stirring conditions. Aggregation curves
(A–C) and ATP release (a–c) were monitored. This experiment is repre-
sentative of four similar experiments from different donors.274 Involvement of the Src Family in Platelet Activation by Collagen
but not extent of shape change in a dose-dependent man-
ner. The inhibition of aggregation and release reaction by
PP1 was observed parallel to that of the tyrosine phosphor-
ylation discussed above, suggesting that PP1 blocks platelet
functions through inhibiting activation of the Src family
and its downstream signals. However, when we used higher
concentrations of collagen (20–50 mg/ml), aggregation and
ATP release reactions became somewhat insensitive to
even 20 mM of PP1, although PP1 still notably delayed be-
ginning of aggregation and ATP release by these concen-
trations of the agonists (data not shown). It is probably be-
cause PP1 could not completely inhibit activation of the
Src family upon strong stimulation of collagen. If it is not,
there may be another possibility that PP1-insensitive bypass
signals might function in platelets stimulated with higher
concentrations of collagen. Although previous studies have
shown that platelets are enriched in the Src family kinases
(31–36), this is the first report demonstrating that the Src
family is functionally related to platelet activation.
The collagen-stimulated tyrosine phosphorylation in-
cluding Syk and PLCg2 is compromised by blocking of
a2b1 with anti-a2b1 mAbs (14, 48) or proteolytic cleavage
of the b1 subunit with the snake venom metalloproteinase
Jararhagin (49), suggesting that a2b1 is also essential for the
collagen signals. However, direct cross-linking of a2b1
alone with mAbs does not cause platelet activation and
protein tyrosine phosphorylation (14). In contrast to our
present findings on the GPVI–FcRg complex, a2b1 has not
been shown to be physically associated with protein ty-
rosine kinases in platelets (48, 49). On the other hand, cross-
linking the GPVI–FcRg complex with anti-GPVI F(ab9)2,
convulxin, or collagen-related peptides, which also stimu-
late platelets via GPVI (50), causes platelet activation and
tyrosine phosphorylation of proteins including FcRg, Syk,
and PLCg2 independently of a2b1 (8, 10–12, 18, 51, 52).
In GPVI-deficient platelets, collagen stimulates a2b1-depen-
dent activation of Src and tyrosine phosphorylation of mul-
tiple proteins but not that of Syk, PLCg2, and Vav (9).
These data seem to support the two-site, two-step model of
platelet activation by collagen (53, 54). At the first step of
the platelet–collagen interaction, a2b1 plays a critical role in
adhesion and might modulate the GPVI–FcRg complex-
mediated responses including protein tyrosine phosphoryla-
tion as a coreceptor, leading to aggregation and release reac-
tion. Roles of the other receptors (2, 5, 6) remain to be less
clear than a2b1 and the GPVI–FcRg complex in the col-
lagen signals. Platelets from patients lacking GPIV (the
Naka-negative phenotype) aggregate (55) and show tyrosine
phosphorylation (56) normally to collagen. However, GPIV
may play some roles in the collagen-induced tyrosine phos-
phorylation, since GPIV is physically associated with Fyn,
Yes, and Lyn (36). Further studies are necessary to elucidate
the complete nature of collagen signals through the GPVI–
FcRg complex, a2b1, and possibly others.
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